1-溴-2,6-萘啶-3-胺 | 3611-11-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 1-溴-2,6-萘啶-3-胺
• 英文名称: 1-bromo-2,6-naphthyridin-3-amine
• 英文别名: 2-Amino-1-bromo-2.6-naphthyridin；1-Brom-3-amino-2.6-naphthyridin；1-bromo-[2,6]naphthyridin-3-ylamine
• CAS: 3611-11-8
• 化学式: C₈H₆BrN₃
• mdl: MFCD00160697
• 分子量: 224.06
• InChiKey: XCIQIUBGAYVLLE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-溴-2,6-萘啶-3-胺 在 palladium 10% on activated carbon 、 氢气 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 25.0 ℃ 、103.42 kPa 条件下， 以61 %的产率得到3-Amino-2.6-naphthyridin
  参考文献：
  名称：

  [EN] METHODS FOR TREATING NEUROLOGICAL DISORDERS
  [FR] MÉTHODES DE TRAITEMENT DE TROUBLES NEUROLOGIQUES

  摘要：

  This disclosure provides compounds and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) DYRK1A activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., a neurological disorder) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

  公开号：

  WO2023107723A2
• 作为产物：
  描述：

  3-溴-4-氰基吡啶 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium tert-butylate 、 氢溴酸 、 溶剂黄146 作用下， 以 1,4-二氧六环 为溶剂， 反应 12.5h， 生成 1-溴-2,6-萘啶-3-胺
  参考文献：
  名称：

  [EN] METHODS FOR TREATING NEUROLOGICAL DISORDERS
  [FR] MÉTHODES DE TRAITEMENT DE TROUBLES NEUROLOGIQUES

  摘要：

  This disclosure provides compounds and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) DYRK1A activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., a neurological disorder) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

  公开号：

  WO2023107723A2

文献信息

• 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor
  申请人：Calvo R. Raul

  公开号：US20060116368A1

  公开（公告）日：2006-06-01

  This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to hetero isonipecotic amides that are potent modulators of VR1 which are useful for the treatment and prevention of disease conditions in mammals.

  这项发明涉及辣椒素受体VR1配体。更具体地说，这项发明涉及对VR1具有潜在调节作用的杂环异尼泊酸酰胺，这些化合物对于治疗和预防哺乳动物的疾病状况是有用的。
• 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER
  申请人：Dorsch Dieter

  公开号：US20130102603A1

  公开（公告）日：2013-04-25

  The present invention relates to novel [1,8]naphthyridine derivatives of formula (I) and to the use of such compounds in which the inhibition, regulation and/or modulation of signal transduction by ATP consuming proteins like kinases plays a role, particularly to inhibitors of TGF-beta receptor kinases, and to the use of such compounds for the treatment of kinase-induced diseases, in particular for the treatment of tumors.

  本发明涉及公式（I）的新型[1,8]萘啶衍生物，以及利用这些化合物在ATP消耗蛋白质如激酶中发挥作用的信号传导的抑制、调节和/或调控，特别是TGF-beta受体激酶的抑制剂，以及利用这些化合物治疗激酶诱导疾病，特别是治疗肿瘤的用途。
• NITROGENOUS HETEROCYCLIC COMPOUNDS
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1067123A1

  公开（公告）日：2001-01-10

  The present invention relates to nitrogen-containing heterocyclic compounds represented by formula (I): wherein W represents 1,4-piperazinediyl, etc.; U represents NR1R2 (wherein R1 represents a hydrogen atom, a substituted or unsubstituted alkyl group, etc.; and R2 represents a hydrogen atom, etc.), OR4, or SR5; V represents an oxygen atom, a sulfur atom, N-R6, or CR7R8, at least one of X, Y and Z represents a nitrogen atom, and the others are the same or different, and each represents a nitrogen atom or C-RA; and D1, D2, D3 and D4 each independently represent C-RB, a nitrogen atom, an oxygen atom, a sulfur atom, etc., optional adjoining two among D1 to D4 are combined to represent a nitrogen atom, N-R2A, an oxygen atom, a sulfur atom, etc., or optional adjoining two selected from D1 to D4 represent C-RB'' (wherein two RB''s are combined to represent substituted or unsubstituted alicyclic alkene, substituted or unsubstituted pyrrole, substituted or unsubstituted pyrazole, etc.; or pharmaceutically acceptable salts thereof.

  本发明涉及式（I）所代表的含氮杂环化合物： 其中 W 代表 1，4-哌嗪二基等；U 代表 NR1R2（其中 R1 代表氢原子、取代或未取代的烷基等；R2 代表氢原子等。)、OR4 或 SR5；V 代表氧原子、硫原子、N-R6 或 CR7R8，X、Y 和 Z 中至少有一个代表氮原子，其他的相同或不同，各自代表氮原子或 C-RA；D1、D2、D3 和 D4 各自独立地代表 C-RB、氮原子、氧原子、硫原子等、D1至D4中任选相邻的两个结合代表氮原子、N-R2A、氧原子、硫原子等，或任选相邻的选自D1至D4的两个代表C-RB''（其中两个RB''结合代表取代或未取代的脂环烯、取代或未取代的吡咯、取代或未取代的吡唑等）；或其药学上可接受的盐。
• Fused ring compounds
  申请人：Genentech, Inc.

  公开号：US11236068B2

  公开（公告）日：2022-02-01

  This invention pertains to fused ring compounds of Formula (I), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods of treatment by their administration.

  本发明涉及式（I）的融合环化合物（如本文进一步详述），该化合物可用于抑制 Ras 蛋白，还涉及包含这些化合物的组合物以及通过施用这些化合物进行治疗的方法。
• 2,4-DIARYL-SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER
  申请人：Merck Patent GmbH

  公开号：EP2585461B1

  公开（公告）日：2020-02-26